Study to Evaluate the Efficacy and Safety of Benralizumab in Adult Patients With Mild to Moderate Persistent Asthma
Public ClinicalTrials.gov record NCT02322775. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab in Adult Patients With Mild to Moderate Persistent Asthma.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this trial is to confirm the safety and clinical benefit of benralizumab administration in asthma patients with mild to moderate persistent asthma in order to gain an understanding of the benefit/risk of benralizumab across the spectrum of asthma disease.
Study identification
- NCT ID
- NCT02322775
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 211 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 2, 2015 (Actual)
- Primary completion
- Oct 7, 2015 (Actual)
- Completion
- Oct 7, 2015 (Actual)
- Last update posted
- Aug 15, 2017
2015
United States locations
- U.S. sites
- 17
- U.S. states
- 10
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Los Angeles | California | 90048 | — |
| Research Site | Rolling Hills Estates | California | 90274 | — |
| Research Site | Clearwater | Florida | 33756 | — |
| Research Site | Orlando | Florida | 32825 | — |
| Research Site | Blue Island | Illinois | 60406 | — |
| Research Site | Skillman | New Jersey | 08558 | — |
| Research Site | Charlotte | North Carolina | 28207 | — |
| Research Site | Monroe | North Carolina | 28112 | — |
| Research Site | Raleigh | North Carolina | 27607 | — |
| Research Site | Winston-Salem | North Carolina | 27103 | — |
| Research Site | Cincinnati | Ohio | 45231 | — |
| Research Site | Grove City | Ohio | 43123 | — |
| Research Site | Oklahoma City | Oklahoma | 73103 | — |
| Research Site | Medford | Oregon | 97504 | — |
| Research Site | Spartanburg | South Carolina | 29303 | — |
| Research Site | El Paso | Texas | 79903 | — |
| Research Site | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 40 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02322775, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 15, 2017 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02322775 live on ClinicalTrials.gov.